In a move that has sparked a heated debate, the government of Guinea-Bissau has suspended a controversial US-funded study on hepatitis B vaccination in the country. The study, which was set to involve withholding the vaccine from some newborns, has raised significant ethical concerns among African health leaders.
The study, led by Danish researchers, was intended to examine the overall health effects of administering the hepatitis B vaccine alongside other routine childhood immunizations. However, the plan to withhold the vaccine from a control group of 7,000 infants until they reached six weeks of age has been widely criticized as unethical.
Quinhin Nantote, the recently appointed Minister of Health in Guinea-Bissau, confirmed to journalists that the trial has been “cancelled or suspended” due to inadequate scientific review. He expressed concerns about the study’s design, stating that the ethics committee in Guinea-Bissau had not properly addressed the issue of withholding a crucial vaccine from newborns.
In response, the Africa Centres for Disease Control and Prevention (Africa CDC) has stepped in to assist Guinea-Bissau in reviewing the study. Jean Kaseya, the Director-General of the Africa CDC, emphasized that the decision to halt the trial ultimately rests with the Guinean authorities. “It’s the sovereignty of the country,” he said, adding that the Africa CDC will support the decision made by the Ministry of Health.
The controversy has also sparked a war of words between the Africa CDC and the US Department of Health and Human Services (HHS). HHS officials have questioned the credibility of the Africa CDC, accusing the organization of engaging in a “public-relations campaign” rather than addressing the scientific facts. However, Kaseya refuted these claims, highlighting the Africa CDC’s crucial role in responding to global health emergencies.
Abdulhammad Babatunde, a medical doctor and global health researcher in Nigeria, emphasized the importance of conducting research that aligns with the needs and priorities of African communities. “Africans want to solve Africa’s problems, not satisfy the curiosity of the funders,” he said.
The decision to suspend the study has been praised by many, including Babatunde, who criticized the original design for withholding a crucial vaccine from some infants. He argued that the control group should have received the standard of care, while the intervention group should have received potentially better care.
As the situation unfolds, the spotlight remains on the ethical considerations surrounding research conducted in low-resource settings. Experts say the most important voice in this debate is that of Guinea-Bissau’s Ministry of Health, which is responsible for protecting the health and wellbeing of all Bissau-Guineans.
